AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6126475 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 40
Study 6126475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30151373 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Number of subjects: 80
Study 30151373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 26179466 — intervention group
Group type: EXPERIMENTAL
Intervention: BITE supervision
Number of subjects: 42
Study 26179466 — intervention group
Group type: COMPARATOR
Intervention: DVB supervision
Number of subjects: 42
Study 24154682 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg once daily)
Number of subjects: 1
Study 22088611 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 327
Study 22088611 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 327
Study 22088611 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory commands to harm or kill the self
Number of subjects: 327
Study 22088611 — intervention group
Group type: EXPERIMENTAL
Intervention: Delusions with themes pertaining to the paranormal
Number of subjects: 327
Study 22088611 — intervention group
Group type: EXPERIMENTAL
Intervention: Delusions with references to celebrities
Number of subjects: 327
Study 20166783 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 18760125 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-management (SM) skills training in combination with HF education
Number of subjects: 902
Study 18760125 — intervention group
Group type: COMPARATOR
Intervention: HF education alone (control)
Number of subjects: 902
Study 15973062 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ramosetron
Number of subjects: 56
Study 15973062 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous granisetron
Number of subjects: 56
Study 15973062 — intervention group
Group type: COMPARATOR
Intervention: Dopamine D2 receptor-blocker (historical control)
Number of subjects: 56
Study 12204841 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with saquinavir soft gel, zalcitabine and zidovudine for 52 weeks
Number of subjects: 95
Study 12204841 — intervention group
Group type: COMPARATOR
Intervention: Switching to nelfinavir, lamivudine and zidovudine for further 52 weeks
Number of subjects: 95
Study 12204841 — intervention group
Group type: EXPERIMENTAL
Intervention: High viral load and presence of RT mutations at baseline
Number of subjects: 95
Study 12204841 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline viral load and development of genotypic mutations on therapy
Number of subjects: 95
Study 12204841 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma saquinavir concentration < 50 mg/ml at 4 weeks
Number of subjects: 95
Study 10663322 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic lavage
Number of subjects: 16
Study 10663322 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative regime
Number of subjects: 16
Study 8803522 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg orally
Number of subjects: 12
Study 8803522 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg orally
Number of subjects: 12
Study 8803522 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg intravenously
Number of subjects: 12
Study 1618070 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg)
Number of subjects: 10
Study 1618070 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (10 mg)
Number of subjects: 10
Study 1618070 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (2.5 mg and 5 mg)
Number of subjects: 10
Study 6705640 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg sublingually/buccally)
Number of subjects: 7
Study 6705640 — intervention group
Group type: EXPERIMENTAL
Intervention: Propantheline bromide (15 mg orally)
Number of subjects: 7
Study 6705640 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and propantheline bromide
Number of subjects: 7
Study 6705640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31622374 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg D-cycloserine (DCS)
Number of subjects: 81
Study 31622374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 29220679 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 0
Study 26908401 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (high-dose edoxaban regimen - 60 mg daily; lower-dose edoxaban regimen - 30 mg daily) with SAPT (aspirin 92.5%)
Number of subjects: 4912
Study 26908401 — intervention group
Group type: COMPARATOR
Intervention: Edoxaban (high-dose edoxaban regimen)
Number of subjects: 4912
Study 26908401 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (high-dose edoxaban regimen) with SAPT
Number of subjects: 4912
Study 26908401 — intervention group
Group type: COMPARATOR
Intervention: Warfarin without SAPT
Number of subjects: 4912
Study 26908401 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin with SAPT
Number of subjects: 4912
Study 26908401 — intervention group
Group type: COMPARATOR
Intervention: Edoxaban (lower-dose edoxaban regimen) without SAPT
Number of subjects: 4912
Study 26908401 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (lower-dose edoxaban regimen) with SAPT
Number of subjects: 4912
Study 25089537 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly oral dose of 0.875 mg vitamin D₃ (vitD₃)
Number of subjects: 129
Study 25089537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 25089537 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR4L stimulation
Number of subjects: 129
Study 22706941 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-min stage duration
Number of subjects: 28
Study 22706941 — intervention group
Group type: COMPARATOR
Intervention: 3-min stage duration
Number of subjects: 28
Study 22706941 — intervention group
Group type: COMPARATOR
Intervention: 6-min stage duration
Number of subjects: 28
Study 22706941 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% PPO with prior maximal incremental test
Number of subjects: 28
Study 22706941 — intervention group
Group type: COMPARATOR
Intervention: 50% PPO without prior maximal incremental test
Number of subjects: 28
Study 21120294 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 shocks at a rate of 60 impulses per minute
Number of subjects: 299
Study 21120294 — intervention group
Group type: COMPARATOR
Intervention: 4000 shocks at 90 impulses per minute
Number of subjects: 299
Study 21120294 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 shocks at a rate of 60 impulses per minute for stones smaller than 10 mm
Number of subjects: 299
Study 21120294 — intervention group
Group type: COMPARATOR
Intervention: 4000 shocks at 90 impulses per minute for stones smaller than 10 mm
Number of subjects: 299
Study 21120294 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 shocks at a rate of 60 impulses per minute for stones bigger than 10 mm
Number of subjects: 299
Study 21120294 — intervention group
Group type: COMPARATOR
Intervention: 4000 shocks at 90 impulses per minute for stones bigger than 10 mm
Number of subjects: 299
Study 18545061 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg/day of extract of ginkgo biloba (EGb) for 12 weeks
Number of subjects: 42
Study 18545061 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 42
Study 15706460 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 41
Study 15706460 — intervention group
Group type: COMPARATOR
Intervention: Trimipramine
Number of subjects: 41
Study 12595862 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (25 g daily for 6 weeks)
Number of subjects: 24
Study 12595862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10571339 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescein angiography (FA)
Number of subjects: 100
Study 10571339 — intervention group
Group type: COMPARATOR
Intervention: No fluorescein angiography (FA)
Number of subjects: 100
Study 8701398 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin (10, 15 or 20 mg s.c. b.i.d.)
Number of subjects: 148
Study 8701398 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (5000 IU s.c. t.i.d.)
Number of subjects: 148
Study 1649267 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CE'P and MEC' regimens)
Number of subjects: 128
Study 1649267 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 128
Study 6378303 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (tricyclic antidepressant)
Number of subjects: 12
Study 6378303 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorgyline (monoamine oxidase inhibitor)
Number of subjects: 12
Study 6378303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30777471 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (400 mg) for 12-14 weeks
Number of subjects: 34
Study 30777471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 30777471 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical removal of endometritic lesions
Number of subjects: 34
Study 29722128 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI-free everolimus regimen
Number of subjects: 497
Study 29722128 — intervention group
Group type: COMPARATOR
Intervention: Standard CNI
Number of subjects: 497
Study 29722128 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-exposure CNI with everolimus
Number of subjects: 497
Study 27908954 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-impregnated dressings
Number of subjects: 100
Study 27908954 — intervention group
Group type: COMPARATOR
Intervention: Standard dressings
Number of subjects: 100
Study 25006719 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab monotherapy (4-week trials)
Number of subjects: 0
Study 25006719 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab monotherapy (12-week trial)
Number of subjects: 0
Study 25006719 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab plus topical glucocorticoids (4-week trial)
Number of subjects: 0
Study 25006719 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus topical glucocorticoids (4-week trial)
Number of subjects: 0
Study 25006719 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study 21345681 — intervention group
Group type: EXPERIMENTAL
Intervention: Unicompartmental knee replacement (UKA)
Number of subjects: 56
Study 21345681 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 56
Study 21345681 — intervention group
Group type: COMPARATOR
Intervention: TKA
Number of subjects: 56
Study 21345681 — intervention group
Group type: EXPERIMENTAL
Intervention: UKA
Number of subjects: 56
Study 20211113 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid extraction and soaking in water
Number of subjects: 0
Study 20211113 — intervention group
Group type: COMPARATOR
Intervention: Control (no lipid extraction or soaking)
Number of subjects: 0
Study 17961725 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (SCT)
Number of subjects: 0
Study 17961725 — intervention group
Group type: COMPARATOR
Intervention: Nonmyeloablative chemotherapy
Number of subjects: 0
Study 17961725 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous mobilized peripheral blood stem cell (PBSC) transplantation
Number of subjects: 0
Study 18290397 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous deferoxamine (130 mg/kg per day over 10-14 hours for 5 consecutive days)
Number of subjects: 15
Study 18290397 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous deferoxamine
Number of subjects: 15
Study 15471837 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐pertechnetate per‐rectal portal scintigraphy (PPS)
Number of subjects: 22
Study 15471837 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinically well children)
Number of subjects: 22
Study 11387540 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help kit and fully covered benefits for OTC nicotine replacement therapy (NRT) gum and patch, and participation in a group behavioural cessation programme with no patient cost sharing
Number of subjects: 1204
Study 11387540 — intervention group
Group type: COMPARATOR
Intervention: Self-help kit (video and pamphlet)
Number of subjects: 1204
Study 9263614 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone (3 x 200 mg/day)
Number of subjects: 460
Study 9263614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study 8280818 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole once daily (second 4 weeks)
Number of subjects: 313
Study 8280818 — intervention group
Group type: COMPARATOR
Intervention: 20 mg omeprazole once daily (second 4 weeks)
Number of subjects: 313
Study 8280818 — intervention group
Group type: COMPARATOR
Intervention: 20 mg omeprazole (4 weeks) then 20 mg (second 4 weeks)
Number of subjects: 313
Study 8280818 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole (4 weeks) then 40 mg (second 4 weeks)
Number of subjects: 313
Study 3545418 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-valent pneumococcal vaccine
Number of subjects: 189
Study 3545418 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 189
Study 30644785 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO group (800 ml the evening before and 400 ml 2 hours before anesthesia)
Number of subjects: 58
Study 30644785 — intervention group
Group type: COMPARATOR
Intervention: FAST group (overnight fasting)
Number of subjects: 58
Study 30570132 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib alone
Number of subjects: 14
Study 30570132 — intervention group
Group type: COMPARATOR
Intervention: Regorafenib with concomitant esomeprazole
Number of subjects: 14
Study 30570132 — intervention group
Group type: COMPARATOR
Intervention: Regorafenib with esomeprazole 3 hours prior
Number of subjects: 14
Study 28142059 — intervention group
Group type: EXPERIMENTAL
Intervention: CpG-ODN plus standard of care (SOC)
Number of subjects: 81
Study 28142059 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 81
Study 26380366 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational program (12 weekly 1.5-hour sessions)
Number of subjects: 106
Study 23412645 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning Therapy (cognitive intervention program)
Number of subjects: 156
Study 23412645 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 156
Study 21385479 — intervention group
Group type: EXPERIMENTAL
Intervention: Early removal of nasogastric tube (NGT) 12 hours after operation
Number of subjects: 43
Study 21385479 — intervention group
Group type: COMPARATOR
Intervention: Control group with NGT remaining until first flatus
Number of subjects: 43
Study 21385479 — intervention group
Group type: EXPERIMENTAL
Intervention: Early removal of NGT
Number of subjects: 43
Study 20545092 — intervention group
Group type: EXPERIMENTAL
Intervention: Retainers fitted to the test group
Number of subjects: 15
Study 20545092 — intervention group
Group type: COMPARATOR
Intervention: Control group (no retainers)
Number of subjects: 15
Study 17324377 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth preparation for full crown and application of one‐step self‐etch adhesive (iBond Gluma inside)
Number of subjects: 20
Study 17324377 — intervention group
Group type: COMPARATOR
Intervention: Sound intact teeth (control group)
Number of subjects: 20
Study 17324377 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth prepared for full crown and extracted within 2h
Number of subjects: 20
Study 17324377 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth coated with one‐step self‐etch adhesive and extracted after 24h
Number of subjects: 20
Study 17324377 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth coated with one‐step self‐etch adhesive and extracted after 48h
Number of subjects: 20
Study 14963465 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil (Av group; n=11)
Number of subjects: 55
Study 14963465 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (Sv group; n=12)
Number of subjects: 55
Study 14963465 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P group; n=12)
Number of subjects: 55
Study 14963465 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil (A group; n=10)
Number of subjects: 55
Study 14963465 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (S group; n=10)
Number of subjects: 55
Study 12351304 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsicum plaster at K-D2 point
Number of subjects: 160
Study 12351304 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsicum plaster at P6 point
Number of subjects: 160
Study 12351304 — intervention group
Group type: COMPARATOR
Intervention: Inactive tape in control group
Number of subjects: 160
Study 9835498 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (3 microgram/kg/min)
Number of subjects: 71
Study 9835498 — intervention group
Group type: COMPARATOR
Intervention: No dopamine
Number of subjects: 71
Study 8528892 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (type I glucocorticoid receptor antagonist), administered in increasing doses, orally.
Number of subjects: 0
Study 8528892 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered orally.
Number of subjects: 0
Study 2909317 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg.h
Number of subjects: 60
Study 2909317 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg.h
Number of subjects: 60
Study 30099833 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid solution (Transamin inj/sol 500 mg/5 mL) infused wet dressing for 20 minutes
Number of subjects: 20
Study 30099833 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling with tranexamic acid solution topical application followed by tranexamic acid solution infused dressing therapy every 15 days for four sessions
Number of subjects: 20
Study 28976933 — intervention group
Group type: EXPERIMENTAL
Intervention: Black beans with rice
Number of subjects: 12
Study 28976933 — intervention group
Group type: EXPERIMENTAL
Intervention: Chickpeas with rice
Number of subjects: 12
Study 28976933 — intervention group
Group type: COMPARATOR
Intervention: Plain white rice (control)
Number of subjects: 12
Study 25639957 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation/Lecture Hybrid
Number of subjects: 38
Study 25639957 — intervention group
Group type: COMPARATOR
Intervention: Lecture-Only Control
Number of subjects: 38
Study 23477572 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy and radiation therapy (ADT‐RTH)
Number of subjects: 60
Study 23477572 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy only (RTH)
Number of subjects: 60
Study 23477572 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term ADT (n = 17)
Number of subjects: 60
Study 23477572 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term ADT (n = 11)
Number of subjects: 60
Study 21684281 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg LX1031, given 4 times/day
Number of subjects: 155
Study 21684281 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg LX1031, given 4 times/day
Number of subjects: 155
Study 21684281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 19538418 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin
Number of subjects: 0
Study 19538418 — intervention group
Group type: COMPARATOR
Intervention: Syntometrine
Number of subjects: 0
Study 16684280 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-coated textiles (verum) worn directly on the skin for 2 weeks (35 patients + 2 dropouts)
Number of subjects: 68
Study 16684280 — intervention group
Group type: COMPARATOR
Intervention: Cotton garments (placebo) worn directly on the skin for 2 weeks (22 patients + 9 dropouts)
Number of subjects: 68
Study 15237068 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 23
Study 15237068 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 23
Study 11295717 — intervention group
Group type: EXPERIMENTAL
Intervention: RORS-G (glucose-based reduced osmolarity ORS)
Number of subjects: 95
Study 11295717 — intervention group
Group type: EXPERIMENTAL
Intervention: RORS-R (rice-based reduced osmolarity ORS)
Number of subjects: 95
Study 11295717 — intervention group
Group type: COMPARATOR
Intervention: WHO-ORS (control)
Number of subjects: 95
Study 9229021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (150 micrograms/kg body weight) on day 1 followed by amocarzine (3 mg/kg twice daily after meals) on days 8, 9, and 10
Number of subjects: 100
Study 9229021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin alone
Number of subjects: 100
Study 9229021 — intervention group
Group type: EXPERIMENTAL
Intervention: Amocarzine alone
Number of subjects: 100
Study 9229021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin plus amocarzine
Number of subjects: 100
Study 9229021 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 100
Study 8214507 — intervention group
Group type: EXPERIMENTAL
Intervention: Written pre-operative advice to stop smoking
Number of subjects: 0
Study 8214507 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 3628823 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 118
Study 3628823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 30939898 — intervention group
Group type: EXPERIMENTAL
Intervention: 2013 Caprini risk assessment model (RAM)
Number of subjects: 1078
Study 30939898 — intervention group
Group type: COMPARATOR
Intervention: Prospective department protocol
Number of subjects: 1078
Study 28399902 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus plus trastuzumab and paclitaxel
Number of subjects: 303
Study 28399902 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and paclitaxel
Number of subjects: 303